These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27228069)

  • 1. Sodium content in products used to treat haemophilia.
    Altisent C; Martorell M; de la Sierra A
    Haemophilia; 2016 Jul; 22(4):e324-7. PubMed ID: 27228069
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
    Berntorp E; Shapiro AD; Waters J; Astermark J
    Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues in making a therapeutic choice: recombinant and/or human-derived products.
    Aledort LM
    Haemophilia; 2001 Jan; 7(1):89-90. PubMed ID: 11136386
    [No Abstract]   [Full Text] [Related]  

  • 6. Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?: Reflections on a possible way forward.
    Keipert C; van den Berg HM; Keller-Stanislawski B; Hilger A
    Haemophilia; 2016 Sep; 22(5):647-50. PubMed ID: 27397094
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 9. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myelomonocytic leukaemia associated with acquired haemophilia A: case report and literature review.
    Liang Y; Lu RN; Wang R; Zhang JF; Su W; Li JY; Zhang SJ; Lu H
    Haemophilia; 2015 Jul; 21(4):e341-3. PubMed ID: 25982484
    [No Abstract]   [Full Text] [Related]  

  • 11. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between a serum fraction and FEIBA fraction in haemophilia.
    Hutton RA; Dormandy K; Nour-Eldin F
    New Istanbul Contrib Clin Sci; 1980; 13(1):9-22. PubMed ID: 6774316
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
    Hansson KM; Lindblom A; Elg M; Lövgren A
    Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of treatment logs by haemophilia patients.
    du Treil S; Rice J; Leissinger CA
    Haemophilia; 2010 May; 16(3):545-7. PubMed ID: 20050930
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of joint bleeding in hemophilia.
    Simpson ML; Valentino LA
    Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL; Abshire TC
    Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.